GBG Forschungs GmbH

Quick facts

Marketed products

• Ibandronat · Other
• NX · Gastrointestinal
  Nexium works by reducing the amount of acid produced in the stomach.

Phase 3 pipeline

• epirubicin - cyclophosphamide / docetaxel + bevacizumab · Oncology
  Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Docetaxel is a taxane that stabilizes microtubules, preventing cell division. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), reducing angiogenesis.
• epirubicin - cyclophosphamide / docetaxel + lapatinib · Oncology
  Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Docetaxel is a taxane that stabilizes microtubules, preventing cell division. Lapatinib is a tyrosine kinase inhibitor that blocks the HER2 and EGFR receptors.
• epirubicin - cyclophosphamide / docetaxel + trastuzumab · Oncology
  Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II, while cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Docetaxel is a taxane that stabilizes microtubules, preventing cell division, and trastuzumab is a monoclonal antibody that targets the HER2/neu receptor.
• Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa · Oncology
  This combination regimen uses chemotherapy agents (epirubicin, cyclophosphamide, paclitaxel) to damage cancer cell DNA and inhibit microtubule function, while dabepoetin alfa stimulates red blood cell production to counteract chemotherapy-induced anemia.
• Exemestane and GnRH analogue · Oncology
  Exemestane suppresses estrogen production while a GnRH analogue suppresses ovarian function, providing dual hormonal blockade in premenopausal women with hormone receptor-positive breast cancer.
• Ibandronate, Capecitabine · Oncology
  This combination uses ibandronate to inhibit bone resorption and capecitabine to inhibit thymidylate synthase for antitumor activity.
• non-pegylated liposomal doxorubicin · Oncology
  Non-pegylated liposomal doxorubicin is a chemotherapy medication that works by intercalating DNA strands, thereby inhibiting the progression of the enzyme topoisomerase II and inducing apoptosis in cancer cells.
• Palbociclib PD-0332991 · Oncology
  Palbociclib is a CDK4/6 inhibitor that works by blocking the activity of cyclin-dependent kinases 4 and 6, which are involved in cell cycle progression.
• Tamoxifen and GnRH analogue · Oncology
  Tamoxifen acts as a selective estrogen receptor modulator (SERM) to inhibit estrogen's proliferative effects on breast cancer cells, while GnRH analogue works by downregulating GnRH receptors in the pituitary gland, leading to decreased gonadotropin secretion and subsequently reduced estrogen production.

Phase 2 pipeline

• background treatment
• Capecitabine, Nab-Paclitaxel
• Cyclophosphamide, Methotrexate, 5 FU · Oncology
  Cyclophosphamide is an alkylating agent that interferes with DNA replication, Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, and 5 FU is a thymidylate synthase inhibitor.
• doxorubicin, docetaxel
• doxorubicin, docetaxel, tamoxifen
• PwCb

Phase 1 pipeline

• Pazopanib plus capecitabine

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• GBG Forschungs GmbH portfolio CI brief
• GBG Forschungs GmbH pipeline updates RSS

Frequently asked questions about GBG Forschungs GmbH

Related

• Ibandronat · Other
• NX · Gastrointestinal
• Sector hub: All tracked pharma companies